Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1350091 | 0.79 | LMNA (0.30) | — | |
| SCHEMBL27270645 | 0.78 | ADORA2A (0.34) | ADORA2AADORA1 | |
| SCHEMBL19893974 | 0.74 | ADORA2A (0.36) | ADORA2AADORA1 | |
| SCHEMBL25530095 | 0.74 | — | — | |
| SCHEMBL19024340 | 0.73 | ADORA2A (0.37) | ADORA2AADORA1 | |
| SCHEMBL30755981 | 0.72 | CYP3A4 (0.39) | — | |
| SCHEMBL2625503 | 0.71 | LMNA (0.42) | — | |
| SCHEMBL29770713 | 0.71 | LMNA (0.42) | — | |
| SCHEMBL7255653 | 0.71 | HMGCR (0.37) | — | |
| SCHEMBL1045304 | 0.71 | DRD2 (0.38) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1484330-B1 | Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO KG (DE) | 2005-10-26 | — | — | EP | disclosed |
| US-6919342-B2 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2005-07-19 | — | — | US | disclosed |
| US-20040259882-A1 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-12-23 | — | — | US | disclosed |
| WO-2004108706-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2004-12-16 | — | — | WO | disclosed |
| EP-1484330-A1 | Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259882-A1 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | DRD3, SLC6A3, DRD2 | ADORA2A 133/4885ADORA1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.